Fig. 5 | British Journal of Cancer

Fig. 5

From: Long-term treatment with the PARP inhibitor niraparib does not increase the mutation load in cell line models and tumour xenografts

Fig. 5

The effect of niraparib on the formation of subclonal tumour-specific mutations in PDX models. a, b Tumour growth in animals implanted with the indicated PDX model. The mean and SEM of four independent samples is shown. c The mean number of unique SNVs (top panel), short insertions (middle panel) and short deletions (bottom panel) identified in whole-exome sequence data from tumour samples derived from control or niraparib-treated animals. Red symbols show the values for individual samples; error bars indicate SEM. Significant differences are indicated (p < 0.05, unpaired t test); NS not significant. d, e Allele frequency distribution of SNVs unique to individual samples (blue, the mean of all six sequenced samples of each PDX is shown), and of SNVs common to all samples of the respective PDX (red). f, g Mean triplet mutation spectrum of unique SNVs in the indicated vehicle-treated (top panel) or niraparib-treated (bottom panel) PDX samples. h, i Triplet mutation spectrum of common SNVs in the indicated PDX samples. The labelling of panels f–i is as described under Fig. 2

Back to article page